BioSpace News Archive

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the March 30, 2022 Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) meeting to review the Company’s New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol.

The industry analysis report is considered a valuable source of information about the global Rabies Monoclonal Antibody industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Biocytogen Pharmaceuticals Co., Ltd. announced the opening of the Biocytogen Europe Innovation Center in Heidelberg, Germany.

The plasmid DNA manufacturing market is expected to grow at a CAGR of 21% over the forecast period 2021 to 2027 and to reach valuation of around US$ 320 million by 2027.

ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced financial results for the full year ended December 31, 2021.

CASI Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2021, and provided an update on key highlights for 2022.

Verastem Oncology today announced it has entered into a credit facility with Oxford Finance LLC for up to $150 million that is designed to primarily support the continued development, commercial preparation and potential launches of VS-6766 and defactinib.

Hangzhou Tigermed Consulting Co., Ltd. announced its annual results for the year ended December 31, 2021 (the “Reporting Period”).

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.